UK Prime Minister Boris Johnson said on Monday he hoped that two promising coronavirus vaccine candidates would be approved shortly.
The Medicines and Healthcare Products Regulatory Agency is yet to greenlight the Pfizer-BioNTech and Oxford-AstraZeneca co-labs.
"We're obviously hoping that both the Pfizer-BioNTech vaccine and the Oxford-AstraZeneca vaccine will get approved in the course of the next few days and weeks," he told reporters during a trip to a medical facility.
Asked whether that meant before vaccines would get a go-ahead before Christmas, the prime minister replied "That's the hope."
Johnson stressed that his government could not let the optimist "run away with us." But he added there was every reason to believe that a working vaccine could turn the tide in the struggle against the virus.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU